Skip to main content

Lineage Cell Therapeutics Inc (LCTX) Insider Trading

In the last 90 days, 6 Lineage Cell Therapeutics Inc (LCTX) insiders reported 6 open-market purchases totaling $2,395,298 and no sales. The most recent open-market purchase was reported on Nov 17, 2026. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
1
90-day purchase value
$2,395,298
Corporate buyers
6
Latest transaction
Nov 17, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Nov 17, 2026Michael H. MulroyDirectorOpen Market Purchase30,000$0.87$26,100
Nov 17, 2026Broadwood Partners L.P.Corporate insiderOpen Market Purchase1,000,000$0.77$770,700
Nov 17, 2026Broadwood Capital IncCorporate insiderOpen Market Purchase1,000,000$0.77$770,700
Nov 17, 2026Neal C BradsherCorporate insiderOpen Market Purchase1,000,000$0.77$770,700
Nov 16, 2026Deborah J AndrewsDirectorOpen Market Purchase25,000$0.80$20,000
Nov 16, 2026Brian M CulleyPresident and CEOOpen Market Purchase40,500$0.92$37,098

Common questions

LCTX insider trading FAQ

Are LCTX insiders buying or selling?
Over the last 90 days, LCTX insiders were net buyers, reporting $2,395,298 of open-market purchases and $0.00 of sales.
When was the last LCTX insider purchase?
The most recent open-market purchase of Lineage Cell Therapeutics Inc stock by an insider was reported on Nov 17, 2026, one of 6 purchases in the last 90 days.
Where does LCTX insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that Lineage Cell Therapeutics Inc officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.